Literature DB >> 6485179

Extracorporeal shock-wave lithotripsy of kidney and ureteric stones.

E Schmiedt, C Chaussy.   

Abstract

Extracorporeal shock-wave lithotripsy (ESWL) has become a routine therapy for the management of stone patients at our department. Till now ESWL has been performed on 1,000 patients. Although the indications for this noninvasive treatment have been expanded significantly, 90% of the patients have been stone free after treatment, 9.3% have small remaining stone particles, while only 0.7% have to be operated on. There was no alteration of kidney function after treatment. ESWL has proven to be a safe alternative to surgical stone removal within an increasing indication range.

Entities:  

Mesh:

Year:  1984        PMID: 6485179     DOI: 10.1159/000280975

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  6 in total

1.  In situ extracorporeal shock wave lithotripsy for upper ureteral stones: experience with 65 patients.

Authors:  I Başar; T Gürpinar; A Erkan
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

2.  High-speed photographic evaluation of endoscopic lithotripsy devices.

Authors:  H J Sterenborg; T M de Reijke; J Wiersma; R C Erckens; F H Jogsma
Journal:  Urol Res       Date:  1991

3.  [Extracorporeal shockwave lithotripsy (ESWL). Chronology of the development].

Authors:  F Eisenberger; C Chaussy; B Forssmann
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

4.  [Stone treatment tomorrow and the day after].

Authors:  A Miernik; S Hein; F Adams; J Halbritter; M Schoenthaler
Journal:  Urologe A       Date:  2016-10       Impact factor: 0.639

5.  Experiments with extracorporeal shock wave nephrolithotripsy.

Authors:  A A Li; N I Alekseyeva; L N Gerasimov
Journal:  Int Urol Nephrol       Date:  1989       Impact factor: 2.370

6.  Calyceal stones: fate of shock wave therapy with respect to stone localization.

Authors:  A Koşar; K Türkölmez; K Sarica; Y Z Müftüoğlu; O Gögüş; K Aydos
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.